Skip to main content

Table 1 Clinical, paraclinical, and MRI characteristics of MOG-seropositive NMO patients compared to AQP4-seropositive and AQP4/MOG-seronegative NMO/NMOSD patients

From: Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype

Characteristics MOG+ ( n= 4) AQP4+ ( n= 31) MOG−/AQP4− ( n= 13)
Sex, female 3/4 23/31 8/13
Age (years), median (range)
 At first attack 31 (15 to 55) 38 (15 to 60) 36 (23 to 53)
 At sampling 48 (47 to 56) 46 (20 to 72) 44 (23 to 66)
Age at first attack <18 years 2/4 3/31 0/13
Clinical presentation at first attack
 ON (uni-/bilateral) 2/4 16/31 8/13
 TM (%LETM) 1/4 (100) 10/31 (90) 4/13 (100)
 Both 1/4 5/31 1/13
Second territorial involvement
 ON (uni-/bilateral) 1/4 9/31 4/13
 TM (%LETM) 2/4 (100) 13/31 (92) 8/13 (100)
 NMOSD 0/4 4/31 0/13
 None 1/4 5/31 1/13
Time to second territory involvement (years), mean (range)c 11.3 (1 to 30) 3.2 (0 to 9) 3.4 (0 to 7)a
EDSS, mean (range)
 At sampling 3.6 (2.5 to 5.0) 3.0 (0 to 8.0) 3.5 (0 to 6.5)
 At last follow-up 3.6 (2.5 to 5.0) 3.1 (0 to 10.0) 3.9 (0 to 10)
CSF, OCB pos. 3/3a 5/29b 1/13
MRI brain lesions 2/4 5/31 1/13
Immunomodulatory treatment 4/4 27/31 12/13
Clinical follow-up (years), mean (range) 19 (3 to 35) 11 (3 to 44) 9 (2 to 17)
  1. aNot available n = 1; bNot available n = 2; cExcluding patients with combined ON/TM at disease onset. Abbreviations: AQP4, aquaporin-4; CSF, cerebrospinal fluid; EDSS, Expanded Disability Status Scale; LETM, longitudinally extensive transverse myelitis; MOG, myelin oligodendrocyte glycoprotein; MRI, magnetic resonance imaging; NMO, neuromyelitis optica; NMOSD, neuromyelitis optica spectrum disorder; OCB, oligoclonal bands; ON, optic neuritis; TM, transverse myelitis.